Cortical glucose metabolism in Parkinson's disease without dementia
暂无分享,去创建一个
William J. Jagust | Jamie L. Eberling | Bruce R. Reed | Brian C. Richardson | W. Jagust | B. Reed | J. Eberling | N. Wolfe | B. Richardson | Nicola Wolfe
[1] T. Ozawa,et al. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in parkinson's disease , 1991, Annals of neurology.
[2] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[3] W. Jagust,et al. Single‐Photon Emission Computed Tomography Studies of Regional Cerebral Blood Flow in Multiple Infarct Dementia , 1992 .
[4] D Comar,et al. Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.
[5] R Harrop,et al. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease , 1986, Neurology.
[6] C. Marsden,et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. , 1992, Brain : a journal of neurology.
[7] J. Morrison,et al. Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia. Regional and laminar distribution of neurofibrillary tangles and senile plaques. , 1992, Archives of neurology.
[8] B Mazoyer,et al. Time course of effects of unilateral lesions of the nucleus basalis of Meynert on glucose utilization by the cerebral cortex. Positron tomography in baboons. , 1989, Brain : a journal of neurology.
[9] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[10] R. Ramsay,et al. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. , 1986, Life sciences.
[11] K. Ebmeier,et al. Cerebral blood flow measured by SPECT as a diagnostic tool in the study of dementia , 1989, Psychiatry Research.
[12] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[13] Guillermo M. Alexander,et al. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease , 1985, Brain Research.
[14] W. Jagust,et al. Diminished Glucose Transport in Alzheimer's Disease: Dynamic PET Studies , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] W. W. Moses,et al. A positron tomograph with 600 BGO crystals and 2.6 mm resolution , 1988 .
[16] A. Brun,et al. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading , 1981, Histopathology.
[17] H. Mayberg,et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease , 1990, Annals of neurology.
[18] D. Knopman,et al. Dementia without Alzheimer pathology , 1985, Neurology.
[19] M. Dam,et al. [99mTc]-HM-PAO SPECT in Parkinson's Disease , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] D E Kuhl,et al. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method , 1984, Annals of neurology.
[21] W. Jagust,et al. Cognitive correlates of regional cerebral blood flow in Alzheimer's disease. , 1993, Archives of neurology.
[22] K. Jellinger,et al. New developments in the pathology of Parkinson's disease. , 1990, Advances in neurology.
[23] I. Mena,et al. Temporal-parietal hypoperfusion with single-photon emission computerized tomography in conditions other than alzheimer’s disease , 1990 .
[24] R J Wise,et al. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. , 1985, Brain : a journal of neurology.
[25] J. Mcculloch,et al. Cerebral circulation: effect of stimulation and blockade of dopamine receptors. , 1977, The American journal of physiology.
[26] J V Haxby,et al. High-resolution PET studies in Alzheimer's disease. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[27] K Wienhard,et al. Positron emission tomography in degenerative disorders of the dopaminergic system , 1992, Journal of neural transmission. Parkinson's disease and dementia section.
[28] B Horwitz,et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. , 1988, Journal of clinical and experimental neuropsychology.
[29] G. M. Halliday,et al. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease , 1990, Brain Research.
[30] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[31] E. Hoffman,et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.
[32] R. Ramsay,et al. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.
[33] T. Joh,et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease , 1990, Annals of neurology.
[34] J W Langston,et al. Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys , 1986, Annals of neurology.
[35] J. Coyle,et al. Jo U Rnal of Cerebral Blood Flow and Metabolism Decreased Cortical Glucose Utilization after Ibotenate Lesion of the Rat Ventromedial Globus Pallidus , 2022 .
[36] A. Hakim,et al. Dementia in Parkinson disease , 1979, Neurology.
[37] M. Beal,et al. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.
[38] T Jones,et al. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease , 1985, Neurology.
[39] U. Slager,et al. Pathologic correlates of dementia in Parkinson's disease. , 1986, Archives of neurology.
[40] W. Jagust,et al. Cognitive function and regional cerebral blood flow in Parkinson's disease. , 1992, Brain : a journal of neurology.
[41] I. Mitchell,et al. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus , 1985, Neuroscience Letters.
[42] O. Hornykiewicz,et al. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey , 1991, Neuroscience.
[43] M Schulzer,et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. , 1992, Archives of neurology.
[44] J. Haxby,et al. Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia. , 1986, Archives of neurology.
[45] U. Roessmann,et al. Parkinson disease, dementia, and alzheimer disease: Clinicopathological correlations , 1980, Annals of neurology.
[46] D L Price,et al. Basal forebrain neurons in the dementia of Parkinson disease , 1983, Annals of neurology.
[47] M. Bergstrom,et al. Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism. , 1987, Advances in neurology.
[48] C. Marsden,et al. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.
[49] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[50] J. Trenkler,et al. Single photon emission computed tomography (SPECT) and x-ray CT in patients with dementia , 1989, Psychiatry Research.
[51] D. D. Di Monte,et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. , 1986, Biochemical and biophysical research communications.
[52] Diana Brahams,et al. Medicine and the Law , 1983, The Lancet.
[53] M C Bourdel,et al. (99mTc)-HM-PAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[54] Stephen M. Stahl,et al. Cerebral metabolism of Parkinsonian primates 21 days after MPTP , 1988, Experimental Neurology.
[55] Richard S. J. Frackowiak,et al. Impaired mesial frontal and putamen activation in Parkinson's disease: A positron emission tomography study , 1992, Annals of neurology.